Partner Headlines - AMGN

  1. 2 Biotech Funds Leading Nascent Bull Market: Which Is Right For ...

    Investors Business Daily
  2. QQQ ETF Posts 52-Week High; Energy Stocks Sag As Oil Drops To ...

    Investors Business Daily
  3. What's Driving The Biotech Stock Rally? And Will It Last?

    Investors Business Daily
  4. Are Biotechs Finally Making A Comeback? Here Are 5 Must-Watch ...

    Investors Business Daily
  5. Apple, Facebook, Alphabet, Amazon, Ford, McDonald's Headline ...

    Investors Business Daily
  6. Amgen Beats Q2 Earnings Estimates, Raises Guidance

    Investors Business Daily
  7. Facebook, GoPro, Amgen Beat; Whole Foods Disappoints

    Investors Business Daily
  8. Nasdaq Up As Fed Stands Pat On Rates; Will Apple Break Its Downtrend?

    Investors Business Daily
  9. Alder Biopharma Migraine Drug Holds Up After 6 Months

    Investors Business Daily
  10. This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or ...

    Investors Business Daily
  11. Week In Review: Stock Breakouts, Netflix Subs Snub, Tesla's Plan, ...

    Investors Business Daily
  12. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  13. Chardan Upgrades Regeneron Amid Relative Underperformance To ...

    Benzinga
  14. Gilead, Johnson & Johnson or Roche?

    GuruFocus
  15. Amgen, Celgene Buck Short Interest Trend In Biotech Stocks

    Benzinga
  16. Chardan: Sell Regeneron After Sanofi Drops Patent Infringement ...

    Benzinga
  17. The Generic Drug Battle

    Benzinga
  18. Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch

    IBD
  19. Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, ...

    Benzinga
  20. Pharmaceuticals Turn To Politics To Protect Prices

    Benzinga
  21. Leerink Is Back On Board The Biotech Train

    Benzinga
  22. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD
  23. Plenty of Opportunity to Buy Individual Stocks: John Buckingham

    GuruFocus
  24. Maybe Some Good News For A Big Biotech ETF

    Benzinga
  25. Why Amazon, Microsoft, Xerox And Amgen Are Moving After-Hours

    Benzinga
  26. Earnings Recap For January 28

    Benzinga
  27. FDA Accepts Amgen's Biosimilar Biologics License Application ...

    Benzinga
  28. Regeneron Is Now A Sell For Chardan

    Benzinga
  29. Big Earnings Expectations For Big Biotech

    Benzinga
  30. Amgen's Vectibix, Best Supportive Care Improves Overall Survival ...

    Benzinga
  31. Amgen's Repatha) Approved in Japan as First PCSK9 Inhibitor for ...

    Benzinga
  32. Medicines Company Spikes On Report Of Possible Sale

    IBD
  33. Jim Cramer Likes Amgen

    Benzinga
  34. Write A Prescription For This Healthcare ETF

    Benzinga
  35. Stocks Reverse Higher To Big Gains; Intel Falls After Q4 Results

    IBD
  36. Stocks, Mutual Funds Rose In Q4 Despite Dec. Woes

    IBD
  37. Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

    Benzinga
  38. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  39. Mid-Afternoon Market Update: Netflix Drops Following Baird Downgrade; ...

    Benzinga
  40. Mid-Day Market Update: Baxalta Shares Surge Amid Report Of Shire ...

    Benzinga
  41. Mid-Morning Market Update: Markets Open Lower; Tesla Motors Delivers ...

    Benzinga
  42. Benzinga's Top #PreMarket Gainers

    Benzinga
  43. Alan Fournier Sells GM, Buys Molson Coors Brewing

    GuruFocus
  44. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  45. Dividend Growth Skids To Halt For S&P 500

    IBD
  46. 5 Guru Picks in Volatile Biotech Industry

    GuruFocus
  47. Benzinga's M&A Chatter for Monday December 21, 2015

    Benzinga
  48. Big Cap 20 Stocks Setting Up In Bases

    IBD
  49. Analyzing Amgen's Dividend Hike

    GuruFocus
  50. 3 Biotechs Atlantic Equities Loves And 1 It's Avoiding

    Benzinga
  51. Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma ...

    Benzinga
  52. EC Approves Amgen's IMLYGIC as First Oncolytic Immunotherapy ...

    Benzinga
  53. 4 Top Dividend Plays To Help Cure Stock Price Blues

    IBD
  54. Big Biotech Amgen Facing Pivotal Year In 2016

    IBD
  55. Allergan Among Health Care Holdings in Alan Fournier's Portfolio

    GuruFocus
  56. Benzinga's Top Upgrades

    Benzinga
  57. Benzinga's Top #PreMarket Gainers

    Benzinga
  58. Amgen Shares Move Higher Following Morgan Stanley Upgrade To ...

    Benzinga
  59. Amgen Submits Application to EMA To Expand Indication Of Kyprolis ...

    Benzinga
  60. Amgen Announces New Analyses Presented At #ASH2015 Demonstrate ...

    Benzinga
  61. Amgen Announces Pivotal Head-To-Head ENDEAVOR Study Results Published ...

    Benzinga
  62. Amgen, Merck target cancer

    IBD
  63. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD
  64. LinkedIn, Palo Alto, Regeneron Profit Estimates Rising

    IBD
  65. Application for Amgen's Biosimilar Candidate to Humira, Submitted ...

    Benzinga
  66. Benzinga's M&A Chatter for Tuesday December 1, 2015

    Benzinga
  67. Biotechs Weaken, But These Names Have Bullish Charts

    IBD
  68. EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia ...

    Benzinga
  69. CVS Makes Amgen New BFF

    IBD
  70. CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi

    IBD
  71. European Commission Approves Kyprolis® (carfilzomib) For Combination ...

    Benzinga
  72. PRIMECAP Sells Stake in Technology Company

    GuruFocus
  73. Regeneron Tests Buy Point As New Drug Shows Promise

    IBD
  74. Regeneron Recovers From Clinton Biotech Beat Down

    IBD
  75. Benzinga's M&A Chatter for Tuesday November 10, 2015

    Benzinga
  76. Amgen Issues Presentation of Results from Phase 3 Study Showing ...

    Benzinga
  77. Amgen Announces Etelcalcetide Met Primary Endpoint of Non-Inferiority ...

    Benzinga
  78. ICYMI: Berkshire Hathaway Just Reported Earnings Of $2,769 Per ...

    Benzinga
  79. ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

    Benzinga
  80. Regeneron Q3 Beats Views, But Praluent Launch Slow

    IBD
  81. AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance

    IBD
  82. 10 Stocks To Watch For October 29, 2015

    Benzinga
  83. Buffalo Wild, GoPro Among Flurry Of Late Wed. Earnings

    IBD
  84. Amgen Crushes EPS Views

    IBD
  85. Amgen Q3 Earnings Beat; Sales Growth Best In Years

    IBD
  86. Amgen Posts Upbeat Q3 Results, Lifts Forecast

    Benzinga
  87. Lifelock, Yelp Surge Following Earnings Report; B-Dubs, GoPro ...

    Benzinga
  88. Wild Short Interest Swings For Three Top Biotech Stocks

    Benzinga
  89. Keep an Eye on These 10 Stocks for October 28, 2015

    Benzinga
  90. Stocks End Lower; Apple Up, Twitter Down After Hours

    IBD
  91. Amgen and Cytokinetics Announce Positive Top-Line Results From ...

    Benzinga
  92. Biotech ETFs: Buy, Buy, Buy?

    Benzinga
  93. 10 S&P 100 Companies Paying The Highest And Lowest Taxes

    Benzinga
  94. Amgen Receives CHMP Positive Opinion For IMLYGIC™ (Talimogene ...

    Benzinga
  95. Cowen: In Biotech Earnings We Trust

    Benzinga
  96. Valeant Subpoenaed By Federal Prosecutors On Pricing

    IBD
  97. Valeant Subpoenaed By Federal Prosecutors On Pricing

    IBD
  98. Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy ...

    Benzinga
  99. Eli Lilly Pulls Cholesterol Drug

    IBD
  100. AMGEN

    IBD
Trading Center